Life Science News

Latest updates from the biotech and pharma world

BioPharma Dive 2026-03-04

Moderna to pay up to $2.25B to end mRNA vaccine patent fight

BioPharma Dive 2026-03-04

Blackstone puts $400M into Teva, Sanofi gut disease drug

BioPharma Dive 2026-03-04

Prime to test FDA flexibility with 2-patient gene editing submission

BioPharma Dive 2026-03-04

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial

BioPharma Dive 2026-03-03

Kyowa Kirin abandons touted eczema drug following safety review

BioPharma Dive 2026-03-03

Pierre Fabre seeks to revive US approval chances for spurned cell therapy

BioPharma Dive 2026-03-02

Ascendis wins FDA approval of dwarfism drug

BioPharma Dive 2026-03-02

UniQure says FDA wants another study of Huntington’s gene therapy

BioPharma Dive 2026-03-02

Roche pill succeeds in another MS study, but approval questions linger

BioPharma Dive 2026-03-02

Candid, in a reverse merger with RallyBio, to go public

BioPharma Dive 2026-03-02

Safety concerns spur Aardvark to halt key Prader-Willi drug trial

BioPharma Dive 2026-03-02

Why it’s critical to close open steps in cell therapy manufacturing

BioPharma Dive 2026-02-27

Atrium spins out of Avidity, aiming to target rare heart diseases with RNA

BioPharma Dive 2026-02-27

UniQure falls further on Makary comments

BioPharma Dive 2026-02-27

Moderna’s combination flu, COVID shot wins over European drug regulators

BioPharma Dive 2026-02-27

Generate caps a strong month for biotech IPOs with $400M offering

BioPharma Dive 2026-02-26

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

BioPharma Dive 2026-02-26

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

BioPharma Dive 2026-02-26

Boehringer drug approved in 44 days; BioMarin shelves Roctavian

BioPharma Dive 2026-02-26

Sarepta CEO Doug Ingram to retire, with company at a crossroads

-1 / 14